What is claimed is:

1. Use of a mast cell modulator for the manufacture of a medicament for treating an infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage, wherein the infectious disease is characterized by the presence of:

chymase in a sample from a subject having the infectious disease at a level greater than a reference level of chymase; wherein the reference level is 0.18 ng/mL to 0.5 ng/mL, 0.8 ng/mL to 3.0 ng/mL, or greater than 3.0 ng/mL; wherein the mast cell modulator is selected from the group consisting of a leukotriene antagonist, a protease inhibitor, and a mast cell stabilizer; wherein the infectious disease is a Dengue virus infection; and wherein the sample from the subject is selected from the group consisting of whole blood, blood plasma, and blood serum.

2. The use of claim 1, wherein the chymase reference level is the level of chymase in a control sample.

3. The use of claim 2, wherein the control sample is a sample from a healthy patient, a patient having the mild form of the infectious disease, or a patient having the severe form of the infectious disease.

4. The use of claim 3, wherein the level of chymase is at least two times greater than the level of chymase in the control sample, wherein the control sample is from a healthy patient.

5. Use of a mast cell modulator for the manufacture of a medicament for treating an infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage, wherein the mild form of the infectious disease is characterized by the presence of chymase in a sample from a subject having the infectious disease at a level greater than 0.18 ng/mL to 0.5 ng/mL and at a level less than 3.0 ng/mL; wherein the severe form of the infectious disease is characterized by the presence of chymase at a level greater than 3.0 ng/mL; wherein the mast cell modulator is selected from the group consisting of a leukotriene antagonist, a protease inhibitor, and a mast cell stabilizer; wherein the infectious disease is a Dengue virus infection; and wherein the sample from the subject is selected from the group consisting of whole blood, blood plasma, and blood serum.

6. The use of claim 1 or claim 5, wherein the mast cell modulator comprises a mast cell stabilizer, wherein the mast cell stabilizer comprises a calcium channel blocker, a cytochrome P450 inhibitor or a histamine antagonist.

7. The use of claim 6, wherein the mast cell modulator comprises at least one of cromolyn, nedocromil, pemirolast, lodoxamide, tranilast, glucosamine, N-acetylglucosamine, FPL 52694, aloe vera, quercetin, chondroitin sulfate, dehydroleucodine, mast cell stabilizer TF002, rupatadine, loratadine, cetirizine, clemastime, fexofenadine, diphenhydramine, chlorpheniramine, azelastine, olopatadine, naphazoline, ketotifen, emedastine, and ebrotidine, combinations thereof and pharmaceutical compositions thereof.

8. The use of claim 7, wherein the mast cell modulator comprises cromolyn.

9. The use of claim 1 or claim 5, wherein the mast cell modulator comprises a chymase inhibitor or montelukast.